Zacks Bull and Bear of the Day Highlights: Grupo Televisa, Infineon Tech, deCODE genetics and Commerce Bancorp.

CHICAGO -- Zacks Equity Research highlights Grupo Televisa (NYSE:TV) the Bull of the Day and Infineon Tech (NYSE:IFX) the Bear of the Day. In addition, Zacks Equity Research provides analysis on deCODE genetics, Inc. (Nasdaq:DCGN) and Commerce Bancorp (NYSE:CBH). Full analysis of all four stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all four stocks:

Bull of the Day:

Our Bull of the Day recommendation is for Grupo Televisa (NYSE:TV). We maintain our Buy recommendation on Grupo Televisa GDS' due to the continued strength in its operating results in the first half of 2006, its dominant position in the Mexican television business, the positive short-term outlook for the Mexican economy, and its promising investments in the attractive fast-growing U.S. Hispanic media market. The deal involving Univision was disappointing; nevertheless, we believe Televisa will be able to create its own television network in the U.S.

Bear of the Day:

Our Bear of the Day recommendation is for Infineon Tech (NYSE:IFX). As Infineon closes out its fiscal year 2006, we are concerned that the problems in the auto industry will have a negative effect on the company's AIM business, while its COMs business continues to lose money. Additionally, the proceeds from the Qimonda IPO were lower than expected, and the company's holdings remain over 80% at the time of the offering. We expect Infineon to divest most of its holdings in Qimonda in a timely fashion, although the recent pricing weakness in the DRAM market may have a negative effect on the company's share price. We continue to rate IFX a Sell, with a stock price of $8.50 over the next six months.

Analyst Blog:

deCODE genetics, Inc. (Nasdaq:DCGN), incorporated in 1996, is a genomics and health informatics company that uses genetics and healthcare information to develop drugs, diagnostics, and pharmacogenetics for the healthcare industry. We were pleased to see the recent positive data on phase II candidate DG031. However, on October 5, 2006, the company announced it was suspending the phase III trial due to manufacturing problems. We believe DCGN will trend sideways over the next several months as investors wait for more information regarding the pipeline. We rate the shares a Hold, with a $5.50 target.

We are reiterating our Hold on Commerce Bancorp (NYSE:CBH), while bumping our price target by $1. Q3 earnings are expected next Monday. The mid-quarter update pointed to weak loan growth. We have also revised our interest rate assumptions, and our estimates are falling as a result. Valuation has become extended in our view, and once again CBH is the single most expensive mid-cap in our peer universe. Our new target represents a very weak Hold, but longer term growth is still expected to be above peer levels, and taking too myopic a view of CBH could cause investors to miss significant appreciation. In other words, a six-month horizon is not the best measure for setting the rating on CBH. We view the $0.48 annual dividend as secure.

Get the full analysis of all four stocks by going to http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros by going to http://at.zacks.com/?id=2650.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a)The Zacks Performance Rank performance is the total return of equal weighted simulated portfolios consisting of those stocks with the indicated Zacks Rank net of fees. Results reflect the reinvestment of dividends and other earnings. Simulated results do not represent actual trading and may not reflect the impact that economic and market factors might have had on decision-making if an adviser were actually managing a client's money.

(b)The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.